Erlotinib-resistance
Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas
... Acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) such as erlotinib is a major challenge to achieve an overall clinical benefit of the targeted ...acquired ...
18
Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase
... acquired resistance of erlotinib by regulating the transcripts associated with DNA damage repair and nucleotides metabolism in NSCLC ...to erlotinib resistance in NSCLC cells, we next ...
16
Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma
... acquire resistance to erlotinib relatively ...in erlotinib resistance, we compared the gene expression profiles of erlotinib-resistant (ER) ...vs. erlotinib-sensitive (ES) HNSCC ...
14
Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer.
... to erlotinib (Figure 5b and ...on erlotinib response is currently ...to erlotinib resistance, this does not fully explain the effects of reduced ...
14
<p>Exosomal Transfer of lncRNA H19 Promotes Erlotinib Resistance in Non-Small Cell Lung Cancer via miR-615-3p/ATG7 Axis</p>
... 5-FU resistance in esophageal ...temozolomide resistance in ...drug resistance in Kirsten rat sarcoma (KRAS) mutant tumors, which relied on autophagy for growth and ...inhibited erlotinib ...
15
Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase
... drug resistance contributes to the low survival among PDAC ...inhibitor erlotinib. We selected erlotinib-resistant pancreatic cancer cells from MiaPaCa2 and AsPC1 cell ...of erlotinib- ...
11
YAP promotes erlotinib resistance in human non-small cell lung cancer cells
... promotes resistance to erlotinib in human non-small cell lung cancer (NSCLC) ...promotes erlotinib resistance in HCC827 (exon 19 deletion) ...HCC827 erlotinib-resistance (ER) ...
12
Suppression of c-MET overcomes erlotinib resistance in tongue cancer cells
... Background: Erlotinib is a commonly used molecular-targeted drug for the treatment of tongue ...acquired resistance to erlotinib hampers its therapeutic ...the erlotinib resistance, ...
10
DNA polymerase alpha subunit B is a binding protein for Erlotinib resistance in non-small lung cancer.
... Abstract: Erlotinib inhibits epithelial growth factor receptor (EGFR) kinase activity and is used to treat non-small cell lung cancer ...of Erlotinib resistance, we investigated additional mechanisms ...
14
Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation
... without erlotinib treatment were generated to identify differentially expressed genes that may be associated with erlotinib resistance (Figure 1C and Supplementary Table S1 and Supplementary Figure ...
13
IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib
... in erlotinib-resistant lung cancer cells, compared to their parental counterparts, regardless of the mutational status of EGFR or ...of erlotinib resistance, a robust upregulation of the IL-8 axis is ...
14
Mer receptor tyrosine kinase is frequently overexpressed in human non-small cell lung cancer, confirming resistance to erlotinib
... to erlotinib treatment by decreasing apoptosis ...that erlotinib treatment did not effectively inhibited AKT signaling in otherwise erlotinib-sensitive NSCLC cells upon Mer overexpression, suggesting ...
14
RETRACTED ARTICLE: Excessive mitochondrial fragmentation triggered by erlotinib promotes pancreatic cancer PANC-1 cell apoptosis via activating the mROS-HtrA2/Omi pathways
... group, erlotinib treatment significantly reduced the ratio of EdU-positive cells; this effect was repressed by Mdivi-1 ...after erlotinib treatment ...
16
Original Article RAF1-MEK1-ERK/AKT axis may confer NSCLC cell lines resistance to erlotinib
... T. Erlotinib versus standard chemotherapy as first-line treatment for Euro- pean patients with advanced EGFR mutation- positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 ...
20
Experimental study on the regulation of erlotinib-induced radiosensitization with an anti-c-MET monoclonal antibody
... with erlotinib and radiation and the regulatory effects of blocking the c-MET-PI3K-AKT pathway on the radiosensitizing effect of ...with erlotinib and radiation and provided a new experimental basis for ...
6
Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib assessed with PET imaging in rats
... cancer resistance protein (BCRP, ABCG2), were shown to play pivotal roles in restricting the intestinal absorption of erlotinib ...[7]. Erlotinib is mainly eliminated through hepatobiliary clearance ...
10
MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC)
... treatment with Onartuzumab plus Erlotinib (HR 0.3; p = 0.06) [46]. Recently, data from a phase I/II trial with Crizotinib reported significant clinical responses in patients with MET amplification. Those patients ...
12
Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer
... plus erlotinib, with a median overall survival of ...plus erlotinib and ...plus erlotinib in both overall and progression-free ...plus erlotinib was also found for patients with wild-type ...
6
Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future
... Targeting vascular endothelial growth factor (VEGF) pathway has shown promising results in the treatment of many solid cancers. However, anti-VEGF therapies have been ineffective clinically in treating patients with ...
16
Development and Validation of RP-HPLC Method for the Estimation of Erlotinib in its Pharmaceutical Dosage form.
... Lutz Gotze 35 et.al:development and clinical application of a LC/MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma. Developed and validated a specific, simple and rapid ...
96